10x Genomics plans to ship Atera, an instrument combining whole-transcriptome spatial profiling with single-cell sensitivity and subcellular resolution, in the second half of the year — the most concrete milestone in a vendor roundtable on moving spatial biology into translational and clinical use. The roundtable, published by GEN, gathers executives from 10x Genomics, Bio-Techne, Bruker and Quanterix, all of whom frame the field's next phase as a shift from exploratory imaging toward reproducible assays deployed across large patient cohorts.

Every claim here comes from vendors with instruments and reagents to sell. Readers should weigh the promised trajectories accordingly; none of the executives cited independent benchmark data for their platforms in the piece.

Why location matters for R&D decisions?

Spatial biology preserves tissue context rather than dissociating samples into single cells. Kamila Belhocine, PhD, senior director of spatial biology at 10x Genomics, said: "When you dissociate a tissue into individual cells, you lose something fundamental: where those cells were and how they were organized relative to one another."

She offered a concrete example from oncology. Knowing whether immune cells have infiltrated a tumor core, sit at its margin, or are excluded altogether can indicate different biology and different likely treatment response. The same logic applies to development, cell differentiation and disease progression studies.

For R&D managers, the practical question is whether spatial assays can fit routine workflows. Belhocine named four barriers: "I think about four things: speed, reliability, cost, and interpretability." She noted the first three are engineering problems, while interpretability requires accumulating validated evidence about which spatial signatures are truly actionable. She drew a parallel to single-cell analysis, which was a specialized technique a decade ago before innovation made it scalable and cost-effective; she expects spatial to follow that trajectory.

What is Bio-Techne bringing to multiomics?

Gary Latham, PhD, CTO of Bio-Techne, argued that tissue biology requires joint measurement of proteins and genes. "A fuller understanding of tissue biology requires seeing where proteins and genes are expressed, how they relate, and how they interact within the tissue architecture," he said. His company's COMET Suite automates hyperplex immunofluorescence and multiomics staining, imaging and analysis.

The company's published examples include a 105-plex multiomics panel run on human breast cancer tissue — a HER2-positive tumor with immune infiltrates, imaging HER2, collagen I, CD45 and CD38 — and a prostate cancer sample visualizing fibrosis associated with cancer-associated fibroblasts. Bio-Techne's RNAscope portfolio supports same-section multiomics with 80,000 RNA probes spanning 450 species.

Latham acknowledged that many spatial workflows remain exploratory and manual during discovery. As programs move toward translation, he said, the focus shifts to robustness, reproducibility and validated workflows, with clinical adoption requiring validated panels, automation and throughput suited to routine testing. He identified oncology and immuno-oncology as dominant applications, followed by immunology and neuroscience, and called biodistribution of gene therapies especially high-impact: spatial multiomics can localize an AAV vector, transgene mRNA, or oligonucleotide therapeutics to specific cells and then measure downstream expression changes.

Can high-plex discovery shrink into clinical assays?

Thomas Campbell, PhD, senior director of product management for Bruker Spatial Biology, focused on what he called the discovery-to-translation gap. "A study may identify dozens or hundreds of potentially relevant biomarkers, but a translational or clinically deployable assay demands a much smaller, highly reproducible panel," he said.

Bruker's answer is a portfolio spanning omic layers: CosMx Spatial Molecular Imager for whole-transcriptome views at subcellular resolution with simultaneous RNA and protein measurement; CellScape XR for quantitative spatial proteomics; and GeoMx Digital Spatial Profiler, which profiles the whole transcriptome and more than 1,200 proteins from distinct tissue compartments. Campbell's premise is that no single modality resolves disease complexity, so labs may need to budget for complementary platforms rather than one.

He was explicit about the field's measure of success: "Ultimately, the value of spatial biology will be measured by how effectively we can connect discovery to clinically actionable insights."

What has changed in the plex-sensitivity tradeoff?

Mike Miller, PhD, CTO and CPO at Quanterix, said the historical tradeoff among plex, sensitivity and resolution has narrowed considerably. The remaining challenge, in his framing, is "building a platform that delivers reproducibility, rigor, and clinical-grade integrity at scale."

Quanterix's Akoya PhenoCycler-Fusion platform visualizes and quantifies more than 100 proteins in a single tissue section at single-cell resolution, using molecular barcoding — short oligonucleotide sequences attached to antibodies, with fluorescent reporters that can be reversibly hybridized and removed without restaining tissue. That enables cyclical imaging. The company's new PhenoCode 2.0 chemistry, part of a recent molecular barcoding kit, lets researchers barcode virtually any antibody of their choice, expanding and customizing biomarker panels.

Miller drew the line that vendors themselves acknowledge: the field must bridge "the gap between generating a striking image in discovery and generating a measurement that holds up in a clinical trial or diagnostic setting." What the roundtable does not supply is head-to-head performance data across these platforms, pricing for large-cohort studies, or third-party validation — the evidence a procurement decision would ultimately require.

Belhocine's prediction that AI will accelerate spatial analysis and that larger patient cohorts will yield treatment-response biomarkers remains a projection, not a measured result. The test of that claim will arrive as Atera and competing platforms reach labs and face cohort-scale studies.